Dexamethasone/levofloxacin: Difference between revisions
Appearance
Content deleted Content added
m typo |
+ cite |
||
Line 65: | Line 65: | ||
}} |
}} |
||
'''Dexamethasone/levofloxacin''', sold under the brand name '''Levodexa''', is a [[fixed-dose combination]] medication used for the prevention and treatment of inflammation, and the prevention of infection, associated with [[cataract surgery]].<ref name="Regulatory Decision Summary for Levodexa" /> It contains [[dexamethasone]], a [[corticosteroid]]; and [[levofloxacin]], an [[anti-infective]].<ref name="Regulatory Decision Summary for Levodexa" /> |
'''Dexamethasone/levofloxacin''', sold under the brand name '''Levodexa''', is a [[fixed-dose combination]] medication used for the prevention and treatment of inflammation, and the prevention of infection, associated with [[cataract surgery]].<ref name="Regulatory Decision Summary for Levodexa" /> It contains [[dexamethasone]], a [[corticosteroid]]; and [[levofloxacin]], an [[anti-infective]].<ref name="Regulatory Decision Summary for Levodexa" /> |
||
It was approved for medical use in Canada in December 2023.<ref name="Regulatory Decision Summary for Levodexa" /> |
It was approved for medical use in Canada in December 2023.<ref name="Regulatory Decision Summary for Levodexa" /> |
Latest revision as of 05:30, 8 July 2024
Combination of | |
---|---|
Dexamethasone | Corticosteroid |
Levofloxacin | Anti-infective |
Clinical data | |
Trade names | Levodexa |
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status |
Dexamethasone/levofloxacin, sold under the brand name Levodexa, is a fixed-dose combination medication used for the prevention and treatment of inflammation, and the prevention of infection, associated with cataract surgery.[1][3] It contains dexamethasone, a corticosteroid; and levofloxacin, an anti-infective.[1]
It was approved for medical use in Canada in December 2023.[1]
Medical uses
[edit]Dexamethasone/levofloxacin is indicated for the prevention and treatment of inflammation, and the prevention of infection, associated with cataract surgery in adults.[1]
References
[edit]- ^ a b c d e "Regulatory Decision Summary for Levodexa". Drug and Health Products Portal. 12 December 2023. Retrieved 2 April 2024.
- ^ "Levodexa Product information". Health Canada. 12 December 2023. Retrieved 2 April 2024.
- ^ Rizzo S, Gambini G, De Vico U, Rizzo C, Kilian R (February 2022). "A One-Week Course of Levofloxacin/Dexamethasone Eye Drops: A Review on a New Approach in Managing Patients After Cataract Surgery". Ophthalmology and Therapy. 11 (1): 101–111. doi:10.1007/s40123-021-00435-1. PMC 8770779. PMID 34936061.